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Background: Resistance to radiation treatment remains a major clinical problem for patients with brain cancer.
Medulloblastoma is the most common malignant brain tumor of childhood, and occurs in the cerebellum. Though
radiation treatment has been critical in increasing survival rates in recent decades, the presence of resistant cells in
a substantial number of medulloblastoma patients leads to relapse and death.
Methods: Using the established medulloblastoma cell lines UW228 and Daoy, we developed a novel model system
to enrich for and study radiation tolerant cells early after radiation exposure. Using fluorescence-activated cell
sorting, dead cells and cells that had initiated apoptosis were removed, allowing surviving cells to be investigated
before extensive proliferation took place.
Results: Isolated surviving cells were tumorigenic in vivo and displayed elevated levels of ABCG2, an ABC
transporter linked to stem cell behavior and drug resistance. Further investigation showed another family member,
ABCA1, was also elevated in surviving cells in these lines, as well as in early passage cultures from pediatric
medulloblastoma patients. We discovered that the multi-ABC transporter inhibitors verapamil and reserpine
sensitized cells from particular patients to radiation, suggesting that ABC transporters have a functional role in
cellular radiation protection. Additionally, verapamil had an intrinsic anti-proliferative effect, with transient exposure
in vitro slowing subsequent in vivo tumor formation. When expression of key ABC transporter genes was assessed in
medulloblastoma tissue from 34 patients, levels were frequently elevated compared with normal cerebellum.
Analysis of microarray data from independent cohorts (n = 428 patients) showed expression of a number of ABC
transporters to be strongly correlated with certain medulloblastoma subtypes, which in turn are associated with
clinical outcome.
Conclusions: ABC transporter inhibitors are already being trialed clinically, with the aim of decreasing
chemotherapy resistance. Our findings suggest that the inhibition of ABC transporters could also increase the
efficacy of radiation treatment for medulloblastoma patients. Additionally, the finding that certain family members
are associated with particular molecular subtypes (most notably high ABCA8 and ABCB4 expression in Sonic
Hedgehog pathway driven tumors), along with cell membrane location, suggests ABC transporters are worthy of
consideration for the diagnostic classification of medulloblastoma.
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Tumors of the central nervous system (CNS) are the lead-
ing cause of cancer related childhood death and disability
in developed countries [1]. Of the malignant pediatric
brain tumors, medulloblastoma is the most common and
treatment typically involves surgery, radiotherapy and
chemotherapy [2]. Age of onset, degree of surgical re-
moval and presence of metastatic disease provide useful
criteria to stratify patients into “standard” and “high risk”
groups, however a subset of patients in both groups are
prone to treatment resistance and relapse. Although re-
cent studies show medulloblastoma patients cluster into at
least four distinct groups based on gene expression signa-
tures, it is not yet possible to determine which individuals
will display treatment resistance [3].
Evidence suggests that increased resistance to both
chemotherapy and radiation is a feature of Cancer Stem-
like Cells (CSCs): the subset of cells within a tumor that
have the ability to drive tumor re-growth or to initiate a
metastatic lesion [4-7].
Resistance to radiation can arise from a variety of mecha-
nisms, including enhanced DNA repair, altered apoptotic
responses, tolerance of genomic instability and dormancy
[8]. A key mechanism by which cells resist chemotherapy
drugs is via ATP-binding cassette (ABC) transporters. The
ABC transporter gene family has 50 members in humans,
encoding membrane-bound pumps that transport an as-
sortment of substrates [9]. Four members of this family
have notable roles in multi-drug resistance: ABCG2 (also
known as BCRP), ABCB1 (Pgp/MDR1), ABCC1 (MRP1)
and ABCC2 (MRP2) [10,11]. ABCG2 is of special interest,
as it marks stem cells in a wide range of normal tissues,
including brain, and may have a functional role in main-
taining a non-differentiated state [12]. ABCG2 is also im-
plicated as a CSC marker in diverse malignancies [13,14].
While definitive markers of CSCs and resistant cells re-
main elusive, genes other than ABCG2 are also expressed
in tumor sub-populations enriched for stem-like behavior.
These include other cell surface molecules (e.g. prominin 1
(CD133), FUT4 (CD15)); filaments (e.g. nestin); regulators
of DNA architecture (e.g. BMI1) and mediators of devel-
opmental signaling networks (e.g. genes involved in the
NOTCH, WNT and Sonic Hedgehog (SHH) pathways)
[15,16]. Despite mounting evidence for the existence of
CSCs in brain tumors, markers in medulloblastoma re-
main poorly understood [17,18].
Evidence of increased radiation resistance in brain CSCs
has come mainly from studies of glioma and atypical
teratoid/rhabdoid tumors (AT/RT) for which experimental
isolation depended on CD133 [19-23]. Selection of CD133
positive cells enriches for CSCs in some tumors, but is not
without controversy [17,24,25]. Nonetheless, activation of
the DNA damage response and chromatin remodeling ap-
pear to mediate radiation tolerance in glioma [19,20,22]. Aglioma study using a non-CD133 driven experimental ap-
proach found Hedgehog pathway signaling important for
maintaining radiation tolerant CSCs [26]. However, radi-
ation resistance and its relationship to stem-like behavior
has been much less studied in medulloblastoma. CD133
positive cells from the Daoy line are reported to have in-
creased radiation tolerance, while in vivo work has shown
Nestin expressing medulloblastoma cells to have enhanced
survival after irradiation [27,28].
We undertook the reverse approach of many studies to
examine radiation tolerant medulloblastoma cells. Rather
than isolating cells with a putative marker and then inves-
tigating resistance, we turned the problem around by
selecting surviving cells functionally, followed by a candi-
date gene approach to see if putative stem cell markers
were associated with the radiation tolerance phenotype.
This gave us the potential to identify characteristics
present before radiation was encountered, as well as re-
sponses that might be preferentially up-regulated by cells
after radiation exposure. This approach proved fruitful,
with the discovery of several genes (including ABCG2),
that were elevated in surviving cells. Furthermore, func-
tional experiments indicated that ABC transporters may
play a previously undiscovered role in protecting brain
tumor cells from radiation induced death.
Results
Development of a model system for early enrichment of
radiation tolerant tumor cells
Post-irradiation populations contain large numbers of
cells undergoing necrosis and apoptosis. Although a
pure population of long-term survivors can be obtained
simply by waiting for other cells to die, the time required
means surviving cells proliferate extensively. A culture
based model system was developed to circumvent this
issue and study surviving cells as early as possible
(Figure 1A).
Firstly, established medulloblastoma cell lines (Daoy
and UW228) and early passage cultures of resected me-
dulloblastoma tissue (R001M and R026M) were irra-
diated to generate dose response curves. This was done
with the Clonogenic Colony Forming Assay (CCFA)
when cells had low motility (Figure 1B), and in other
cases by total viability assay (Figure 1C). CCFAs give
more complete data than viability based assays, because
cells must be both alive and proliferative to be counted.
Differences in results from the two types of assay were
observed (for early passage cultures in particular),
reflecting the presence of non-proliferative cells that
were damaged by radiation but that had not yet died in
viability assay data. Both assays are informative for com-
paring the overall health of cell populations before and
after radiation exposure. Our aim was to determine a
dose at which between 1% and 5% of treated cells would
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Figure 1 Post-radiation survivor selection model yields tumor initiating cells. (A) Outline of technique used for the early isolation of
medulloblastoma sub-populations enriched for the most radiation tolerant cells. The method uses Propidium Iodide (PI) and Annexin V to
exclude sensitive cells via Fluorescence Activated Cell Sorting (FACS). (B) Radiation dose response curves for UW228, Daoy and R001M, generated
by Clonogenic Colony Forming Assay (which only includes actively proliferating cells). (C) Radiation dose response curves for Daoy, R001M and
R026M, generated by resazurin based viability assay (measures all cells that have not yet died). (D) Profile of apoptosis initiation over time after
irradiation of Daoy cells, detected by Immunofluorescence using Annexin V (240 to 1700 cells assessed per treatment, over 3 to 7 wells). Error
bars in panels B to D represent +/− 1 SD. “**” = p-value < 0.01, “***” = p-value < 0.001, for control compared with irradiated cells. (E) Tumorsphere
culture of Daoy cells surviving 10 Gy radiation. After an initial lag, independent survivor sub-lines (SLs) yield proliferative sphere cultures, which
like non-irradiated (control) SLs, are able to be proliferated long term (spheres were passaged weekly). (F) Medulloblastoma cells shown in panel
E, that survived 10 Gy, initiated large tumors when implanted into the cerebellum of immuno-compromised mice. Whole brain shown (olfactory
bulbs removed) with typical tumor indicated by arrow.
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was harsh but would provide enough survivor cells for
meaningful analysis. After receiving 10 Gy, Daoy, UW228
and R001M gave 1.3%, 3.8% and 3.2% of cells (res-
pectively) that were able to survive and form colonies
(Figure 1B; R026M cells were unsuitable for CCFA).
The time course of phosphatidylserine (PS) externa-
lization, an early step in apoptosis initiation [29], was
profiled in Daoy and UW228 lines after 10 Gy irradi-
ation, the dose chosen for resistant cell isolation (Daoy
data shown Figure 1D, UW228 results similar). While
high levels of external PS were readily detected after
1 day, peak levels were not reached until two days and
were still significant at three days post-irradiation. For
resistant cell isolation, 10 to 20 million cells wereirradiated and then incubated for three days (i.e. until
after the apoptotic peak). Surviving cells were then iso-
lated by eliminating both dead (Propidium Iodide (PI)
positive) cells and “doomed to die” (Annexin V positive)
cells by Fluorescence-Activated Cell Sorting (FACS).
Non-irradiated cells were sorted in parallel to provide a
comparable control population, in which spontaneous
apoptotic cells (notable in Figure 1D) were eliminated.
Radiation tolerant medulloblastoma cells display stem
behavior and are tumorigenic
Daoy and UW228 cells surviving 10 Gy radiation were
able to proliferate long term in tumorsphere cultures
(Figure 1E). Daoy tumorsphere cells descended from
radiation survivors were assessed in an intracranial
AB
C
D
Figure 2 UW228 medulloblastoma cells surviving 10 Gy
radiation show elevated expression of c-Myc and several ABC
transporters. Pair-matched live non-apoptotic cell populations,
from 0 Gy (control) and 10 Gy treated (surviving) cells in multiple
independent experiments, were isolated using FACS. Analysis by
qRT-PCR showed (A) c-Myc, (B) ABCG2 and (D) ABCA1 are elevated
in surviving cells. Bars show relative gene expression derived from
the mean ΔCt of quadruplicate multiplex assays. To clearly display
variation between experiments (both in terms of magnitudes of
expression and the difference between control and resistant cells),
independent experiments are shown individually. The fold-change
value for each pair-matched experiment is also indicated (being the
relative expression for surviving cells divided by that for control cells,
or 2-ΔΔCt). Error bars (asymmetric on gene expression scale)
represent symmetric +/− 1 SD in the Ct space. When surviving cells
are compared with control cells over all pooled biological
experiments, p-values are <0.05 for all three genes. (C) ABCG2 was
also elevated at the protein level when assessed by flow cytometry.
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This confirmed that the isolated post-irradiation popula-
tion included cells with cancer stem cell properties (the
ability to initiate and recapitulate a tumor; Figure 1F).
Certain stem-associated genes are elevated in
medulloblastoma cells surviving high dose radiation
A candidate gene approach was then undertaken to see
if genes implicated in stem behavior were differently
expressed in Daoy and UW228 radiation survivors.
Quantitative Real Time PCR (qRT-PCR) was performed
on the “Annexin V negative, PI negative” 0 Gy and post-
10 Gy populations. At least three independent FACS
isolation experiments were undertaken for each line. We
did not observe any significant repeatable difference in
mRNA expression with GLI1, PTCH1, HES1, MSI1,
CD133, nestin (NES), GFAP, POU5F1 (OCT4), SOX2,
KLF4, CD15, CD44, BMI1, NANOG, survivin (BIRC5),
XIAP or EPAS1 (HIF2A) in Daoy or UW228 populations
(data not shown). However, two genes were of interest.
For UW228 (but not Daoy) c-Myc (MYC) was consist-
ently elevated in the radiation survivors compared with
the parent population (Figure 2A) and a dramatic
change in the ABC transporter ABCG2 was repeatedly
observed for both lines (Figures 2B and 3A).
Flow cytometry showed ABCG2 is also elevated in ra-
diation survivors at the protein level (Figure 2C). Our
focus then turned to this and the three related genes
that play major roles in chemotherapy resistance. An
additional member, ABCA1, was investigated as its ele-
vation after irradiation has been reported in glioma [30].
The ABCA1 protein transports lipids and has important
roles in cholesterol homeostasis and macrophage engulf-
ment [31]. Significant mRNA changes were not observed
for ABCB1, ABCC1 or ABCC2 in Daoy or UW228 radi-
ation survivors; however the increase in ABCA1, as for
ABCG2, was striking in both lines (Figures 2D and 3B).
AB
Figure 3 Daoy Medulloblastoma cells surviving 10 Gy radiation
show elevated expression of several ABC transporters. Pair-
matched live non-apoptotic cell populations, from 0 Gy (control) and
10 Gy treated (surviving) cells in multiple independent experiments,
were isolated using FACS. Analysis by qRT-PCR shows (A) ABCG2 and
(B) ABCA1 are elevated in surviving cells. Bars show relative gene
expression derived from the mean ΔCt of quadruplicate multiplex
assays. Independent experiments are shown individually, to clearly
display variation between experiments (both in terms of magnitudes
of expression and the difference between control and resistant cells).
The fold-change value for each pair-matched experiment is also
indicated (being the relative expression for surviving cells divided by
that for control cells, or 2-ΔΔCt). Error bars (asymmetric on gene
expression scale) represent symmetric +/− 1 SD in the Ct space. When
surviving cells are compared with control cells over all pooled
biological experiments, p-values are <0.05 for both genes.
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Figure 4 Early passage medulloblastoma cells that survive 10 Gy
radiation show elevated expression of HIF2A and ABCA1. Live
non-apoptotic cell populations of 0 Gy (control) and 10 Gy treated
(surviving) cells for two newly derived human patient cultures, R001M
(A and C) and R026M (B and D), were isolated by FACS. Analysis by
qRT-PCR shows HIF2A (A and B) and ABCA1 (C and D) are elevated in
surviving cells from both patients. Bars show relative gene expression
derived from the mean ΔCt of quadruplicate multiplex assays. The
fold-change value for each pair-matched experiment is also indicated
(being the relative expression for surviving cells divided by that for
control cells, or 2-ΔΔCt). Error bars (asymmetric on gene expression
scale) represent symmetric +/− 1 SD in the Ct space.
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R026M) were then examined using the same FACS-based
radiation survivor isolation model. Elevation of ABCG2
and c-Myc was not observed in radiation tolerant cells
isolated from these cultures (data not shown). However,
HIF2A mRNA was elevated in radiation survivors from
both early passage cultures, though this did not occur in
Daoy or UW228 (Figure 4A and 4B). Most notable was
the dramatic change in ABCA1 levels in radiation survi-
vors, compared with control populations, that was univer-
sally observed in all cells tested including the early
passage cultures (Figure 4C and 4D).
An alternate model involving long-term fractionated
irradiation of UW228 corroborates findings of elevated
ABCA1 and ABCG2 in surviving cells
ABC transporter expression differences were also confirmed
using an alternate strategy for studying radiation tolerantcells. Here eight sub-lines were seeded from the parent
UW228 cells and four were repeatedly exposed to a moder-
ate radiation dose (3 Gy) once per week. The other four
sub-lines were passaged in parallel as controls, without radi-
ation exposure. After twelve weeks the irradiated sub-lines
displayed significantly greater resistance to radiation than
the control sub-lines at high doses (8 and 10 Gy, Figure 5A).
Both ABCA1 and ABCG2 were expressed at higher levels in
sub-lines displaying increased resistance (Figure 5B and 5C).
We used FACS to isolate ABCA1 and ABCG2 express-
ing and non-expressing sub-populations from radiation
naive UW228 and Daoy cultures, to examine whether
expression of ABC transporters prior to irradiation is a
marker for cells that are more likely to display radiation
tolerance. Interestingly, the percentage of cells express-
ing either gene was very low in both lines (0.3% for
ABCG2 (Figure 2C) and 1.5% for ABCA1), and positive
cells did not show increased resistance over negative
cells by CCFA (data not shown). Thus there may be dif-
ferences in the way these genes are controlled in resist-
ant cells in response to radiation, rather than being
intrinsic markers prior to exposure.
AB
C
S
ur
vi
vi
ng
 C
el
ls
 (
%
)
Radiation Dose (Gy)
A
B
C
A
1/
G
A
P
D
H
 m
R
N
A
 le
ve
l
0
0.2
0.4
0.6
0
-52 x10
A
B
C
G
2/
G
A
P
D
H
 m
R
N
A
 le
ve
l
-54 x10
-56 x10
Control Sub-lines Sub-lines with 
Enhanced Resistance
0
20
40
60
80
100
0 2 4 6 8 10
**
Control Sub-lines Sub-lines with 
Enhanced Resistance
Control Sub-lines
(Radiation Naive)
Sub-lines Repeatedly
Exposed to 3 Gy 
*** ***
*
Figure 5 UW228 cells show increased radiation resistance and
increased ABC transporter expression after long-term weekly
radiation exposure. (A) Enhanced radiation resistance of cells
exposed repeatedly to 3 Gy, by resazurin based total viability assay.
Cells were assessed for resistance 2.5 weeks after receiving their final
treatment dose. Mean survival of 4 long-term independently
cultured sub-lines for each treatment shown. Error bars +/− 1 SD,
“***” indicates p-value < 0.001. (B) Elevated expression of ABCA1 and
(C) ABCG2, in the independent sub-lines, by qRT-PCR. Points
represent relative gene expression for each line derived from the
mean ΔCt of quadruplicate multiplex assays. Horizontal bars show
the geometric mean for all sub-lines (“*” indicates p-value < 0.05,
“**” indicates p-value < 0.01).
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http://www.ehoonline.org/content/2/1/26Verapamil mediated sensitization suggests ABC transporters
may have a functional role in radiation protection
To test the hypothesis that ABC transporter proteins
may provide a functional advantage to cells survivingradiation damage, we investigated a range of available
ABC transporter inhibitors to see if these altered the
sensitivity of Daoy or UW228 cells.
The potential role of ABCA1 in radiation protection,
of particular interest due to the universal nature of its
elevation in radiation survivor cells from all patients in-
vestigated, was explored using probucol, which strongly
represses ABCA1 function [32]. No effect on radiation
sensitivity was observed with this compound. Likewise,
specific inhibitors of ABCG2 (FTC and Ko143) failed to
elicit a response. However verapamil (which inhibits
multiple family members rather than just a single ABC
transporter), caused a marked sensitization of Daoy
cells to radiation by both total viability assay (Figure 6A)
and CCFA (Figure 6D).
Verapamil is a drug with complex effects. In addition
to inhibiting ABC transporters, it also blocks L-type
calcium channels [11,33]. Exposing cells to other L-type
calcium channel blockers (diltiazem and nifedipine)
had no effect on radiation sensitivity, showing the
sensitization to radiation is unlikely to be due to
calcium channel effects (Figure 6A). Optical isomers of
verapamil have different potencies as inhibitors, making
them a useful research tool (Figure 6C). The “S” isomer
possesses calcium channel blocking activity that is an
order of magnitude more potent than that of the “R”
isomer (dexverapamil), while both are strong ABC
transport inhibitors [34-36]. Both isomers were simi-
larly effective at sensitizing Daoy cells to radiation,
further suggesting the radiation sensitizing effect is
independent of calcium channel inhibition (Figure 6A).
Transient exposure to verapamil in vitro reduces the
tumorigenicity of medulloblastoma cells in vivo
Verapamil was observed to have an innate anti-
proliferative effect on medulloblastoma cultures, limit-
ing the expansion of cell populations over time
(Figure 6B) and causing a distinct downward shift in
the size distribution of clonogenic colonies (Figure 6F
compared with Figure 6E). In light of this an in vivo
flank xenograft model was used to determine if it
affected the behavior of stem-like (tumor initiating)
cells within cultures. Daoy cells were exposed to R-
verapamil (or carrier) in vitro for 5 days and then equal
numbers of live cells were implanted into mice without
further treatment. This short exposure impeded Daoy
tumorigenicity in the flank xenograft model. Although
almost all mice had palpable tumors by 10 weeks, the
majority of control xenografts were detectable within
three weeks while cells treated with R-verapamil tended
to display delayed tumor formation (Figure 7). Daoy
cells were used in preference to UW228 cells for these
experiments as the latter only gave tumors at low
frequency in preliminary xenograft trials.
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Figure 6 Functional screening experiments show verapamil increases the sensitivity of Daoy medulloblastoma cells to radiation, and
stunts population expansion. (A) Investigation of inhibitors of ABC transport (and controls) and their effect on radiation response (dose = 5 Gy),
using resazurin based cell viability assay. Racemic verapamil sensitized Daoy cells to radiation, as did both component isomers when used
individually. “E” indicates drug carrier = ethanol, “D” indicates carrier = DMSO. Survival score was obtained by dividing mean fluorescence after
drug exposure and irradiation by that of wells experiencing the drug without irradiation. Error bars +/− 1 SD. “***” indicates p-value < 0.001 when
treatments are compared with carrier control. (B) Mean resazurin fluorescence readings for non-irradiated wells of selected treatments in Panel A,
showing verapamil isomers lead to fewer live cells at the end of the 5 day assay period, while the calcium channel inhibitor diltiazem has no
effect. Error bars +/− 1 SD. (C) Summary of current state of knowledge regarding the relative biological potencies of S- and R-verapamil.
(D) R-verapamil is also a radiation sensitizer of Daoy cells in the clonogenic colony formation assay (dose = 5 Gy, 5 flasks per treatment).
Error bars +/− 1 SD. (E) Size distribution histogram of colonies derived from non-irradiated control and (F) non-irradiated R-verapamil treated
cells from experiment in panel D. Mean diameter for each colony calculated using digital image analysis.
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http://www.ehoonline.org/content/2/1/26Reserpine mediated sensitization also suggests a functional
role for ABC transporters in radiation protection
When inhibitor screening was extended to the early pas-
sage cultures, sensitization to radiation was observed with
reserpine, a plant derived indole alkaloid that inhibits mul-
tiple ABC transporters [11,37]. Although reserpine did not
alter the dose response curves of the Daoy, UW228 or
R026M cultures, it was found to increase the sensitivity of
R001M cells to radiation in a dose dependent manner
(Figure 8A). Conversely, the highly reproducible effect of
verapamil on Daoy cells did not occur in the other lines
tested (data not shown), showing that cells derived from
different patients can have distinct molecular weaknesses.
Reserpine was not toxic to R001M cells at the concentra-
tions used (Figure 8B).ABC transporters are expressed in medulloblastoma in
variable patterns and some family members are
associated with particular molecular subtypes.
Since certain ABC transporters: 1) mark cells with stem-
like behavior in various systems, 2) have roles in chemo-
therapy resistance and 3) may be involved in radiation
protection, we surveyed expression of key ABC trans-
porters in freshly resected pediatric medulloblastoma
tissue. Investigation of 34 cases by qRT-PCR showed
ABCG2 and ABCA1 were often expressed (91% and 82%
of patients respectively), while ABCC1 was expressed
universally. In contrast, ABCB1 and ABCC2 were only
detected occasionally (44% and 29% of patients resp-
ectively). Patterns of ABC transporter expression were
highly variable from patient to patient, and levels for one
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compared with normal pediatric cerebellum (Figure 9).
As molecular sub-typing data was unavailable for the
majority of our patient cohort, we turned to a large and
well annotated public medulloblastoma dataset for further
investigations [38]. As in our dataset, ABC transporter
genes tended to be expressed at varying levels for these 62
cases (results shown in Additional files 1, 2, 3). Notable
patterns were discovered in the expression of several ABC
transporters when tumors were clustered by subtype. Of
the five genes focused on in our study, ABCA1 was of note,
as high expression was significantly associated with group
A (WNT associated) tumors and low expression with
groups B (SHH associated) and E. ABCB1 tended to be
more highly expressed in group B, C and D than in the
other two groups (refer Additional file 1; Note that groups
C and D in this dataset are equivalent to “group 4” in the
current consensus nomenclature [39]). The most striking
associations however were with other family members. Our
initial analysis identified a number of ABC transporters that
show significant subtype-related expression trends, with the
highest significance discriminators being ABCA8, ABCB4,
ABCC8 and ABCD2 (refer Additional files 2 and 3).
These findings were then validated using data from
three large independent cohorts [40-43] that included
366 medulloblastoma cases. Expression “heat maps” for
all available ABC transporter family members are shown
in Additional file 4. Previously observed trends were
corroborated, including high expression of ABCA1 in
the WNT subgroup (refer Additional file 5). Data
confirming the association of high ABCA8 and ABCB4
and low ABCC8 expression with the SHH subgroup
(relative to other subgroups and normal cerebellum) is
shown in Figure 10.Discussion
While incremental improvements to surgical, chemo-
therapeutic and radiological procedures continue to in-
crease survival for pediatric brain tumor patients, death
rates and quality of life issues for those who remain in
remission are significant. The key to overcoming limita-
tions of existing treatments is to increase our understand-
ing of tumor cell biology at the level of individual cells.
Towards this goal, we used a functional approach to
investigate medulloblastoma cells displaying high radi-
ation tolerance. FACS was employed to remove dead
and apoptotic cells from irradiated cultures, so that sur-
viving cells could be studied before extensive cell div-
ision took place. This “rapid isolation approach” allowed
study of the tolerant cells or their early descendants, ra-
ther than distant progeny. The “survivor cells” displayed
tumorigenic potential in vivo, showing that they were
indeed “healthy” and retained stem-like behavior. The
finding of elevated levels of ABCG2 in such cells from a
subset of human patients, and of ABCA1 in all patient
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Figure 9 ABC transporter levels in fresh human pediatric medulloblastoma tissue compared with medulloblastoma cell lines and
normal pediatric cerebellar control tissue. Expression of five key members of the ABC Transporter family, relative to GAPDH expression, as
shown by qRT-PCR. Values were derived from the mean ΔCt of triplicate multiplex assays. Error bars (asymmetric on gene expression scale)
represent symmetric +/− 1 SD in the Ct space.
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roles ABC transporters play in chemo-resistance and
stem cell biology. ABCG2 has also been implicated in
cancer susceptibility, as a polymorphism in the human
gene is associated with a change in incidence for several
malignancies [44]. In this study we chose to focus on a
key subset of ABC transporters known to be strong
drivers of drug resistance in human patients, or that play
a known role in stem cell or brain tumor biology. It is
anticipated that other members of this extensive gene
family may also display increased expression in medullo-
blastoma cells after radiation treatment.
Elevated levels of ABC transporters may be observed
in radiation tolerant cells for three reasons: they couldreflect a generalized stress response, they could provide
a functional advantage to irradiated cells, or their ex-
pression might be correlated with other genes that are
functionally involved in resistance. The fact that both
ABCA1 and ABCG2 were elevated in an independent
model of radiation resistance in UW228 cells led us to
further explore the role of the ABC transporter family.
Findings with c-Myc and HIF2A in various patient cul-
tures are also of interest, and are a focus of ongoing
investigation.
ABCA1 and ABCG2 proteins were only expressed on a
small proportion of cells within radiation naive medullo-
blastoma lines. Subsequent analysis showed their expres-
sion did not specifically mark cells that would better
Figure 10 ABCA8, ABCB4 and ABCC8 show distinctive SHH subtype associated expression patterns, relative to other medulloblastoma
subgroups and normal cerebellum. Expression data from the three independent validation cohorts (n = 366 patients total) shown as box and
whisker plots (quartiles and median indicated by box outline and centreline respectively). Asterisks indicate significance of difference in expression
between subgroup of interest and the remaining subgroups (“***” = p-value < 0.001). In addition, comparisons between the subgroup of interest and
normal cerebellum (available for the Boston cohort) were significantly different with a p-value of 0.01 or better for all genes shown. [Note that in the
Toronto experiments some probe sequence overlap was present between ABCC8 and enzyme component gene SDHC, for the plot indicated with “#”.
Analysis of independent SDHC probes in the other analysis sets showed that the SHH subgroup effect seen for the Toronto cohort is likely driven
largely or entirely by ABCC8. There were no confounding issues with the probes for ABCC8 used for the Boston or Heidelberg cohorts].
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greater intrinsic resistance may exist in a “primed” state
and have the ability to express such genes after radiation
is experienced.
Difficulties were anticipated in using RNA-based knock-
down technology to explore the possible functional rele-
vance of expression changes, due to the vast number of
ABC transporter genes in the human genome and their
tendency for overlapping roles, and the fact that we wished
to investigate early passage primary culture cells (which are
challenging to transfect efficiently). Instead, we took advan-
tage of the wide range of readily available compounds
known to inhibit single or diverse ABC transporter
proteins. Use of these led to our discovery that ABC trans-
porters not only contribute to chemotherapy resistance, but
also play a functional role in radiation protection. This find-
ing is based on studies with ABC transporter inhibitors of
two distinct molecular classes. Although the multi-ABC
transporter blockers verapamil and reserpine enhanced
radiation sensitivity, compounds specifically inhibiting just
ABCG2 or ABCA1 had no detectable effect. This suggests
overlapping function of genes, with multiple transporters
having functions that together contribute to radiation
resistance. Thus it appears combinations of transporters
need to be blocked to prevent radio-protective effects. The
fact that reserpine and verapamil sensitized cultures from
different patients may be a reflection of the varied ABC
transporter expression patterns observed between different
medulloblastoma cases, in both our own and publicly
available gene expression datasets.
Results obtained with verapamil and reserpine need to
be interpreted with care, since their channel inhibition
effects extend further than the ABC transporter family.
Verapamil also possesses anti-L-type calcium channel
activity and influences potassium transport. Our finding
that the R-verapamil optical isomer mediates radiation
sensitization at a level indistinguishable from that of
S-verapamil, even though the former only possesses
weak calcium/potassium channel activity, is important
given both are similarly potent in blocking ABC trans-
porters [34-36,45,46]. This suggests the radiation protec-
tion mechanism is ABC transporter driven, although it
is possible that a residual level of anti-cation channel ac-
tivity could saturate a sensitive system. Our second line
of evidence suggests this is not the case, as deliberate
addition of other inhibitors of L-type calcium/potassium
activity did not have any observable effect on radiation
sensitivity. While such experiments implicate ABC
transporters, this does not preclude verapamil having
effects on other undiscovered cellular targets that may
also protect cells from radiation. However, observation
of a similar radiation sensitizing effect with the in-
dependent ABC transporter inhibitor reserpine further
strengthens the case for ABC transporter involvement.Reserpine is used extensively in research due to its po-
tent inhibition of ABC transporters [11,37]. While verap-
amil and reserpine overlap in their inhibition of ABCB1,
their effects on the majority of other individual family
members remain unstudied [11]. In addition to ABC trans-
porters, reserpine also inhibits the vesicular monoamine
transporter (VMAT), which is involved in neurotransmit-
ter movement in the CNS [47]. Although less likely in light
of the verapamil result, it remains possible that the dose
dependent sensitization to radiation observed with re-
serpine was due to neurotransmitter rather than ABC
transporter effects. If this is the case, it would raise the in-
triguing possibility that reserpine may influence radiation
responses by directly manipulating the stem-like properties
of cells, since inhibitors of neurotransmitter pathways are
known to reduce neural stem cell populations [48].
The anti-proliferative effect of verapamil observed in
medulloblastoma lines supports earlier reports of this
phenomenon in various neoplastic cells [49-53]. Though
initially presumed to be due to calcium effects, there is
now evidence that the anti-cancer properties of verapamil
involve non-calcium dependent mechanisms [52,54]. Ver-
apamil is also anti-tumorigenic when given to live animals
harboring meningioma xenografts [55]; however our study
is the first to show transient exposure to verapamil in vitro
has long lasting effects when tumorigenicity is subse-
quently assessed in vivo. This innate anti-tumorigenic
effect may provide a therapeutic bonus (in addition to
chemo- and radiotherapy sensitization), if new generation
drugs with structures similar to verapamil are used in the
treatment of future patients.
Increased expression of ABC transporters, particularly
ABCB1, has been reported after irradiation in several cell
types [56-58]. The exact mechanism by which this is con-
trolled remains largely unexplored, although a number of
ABC transporters are known to be up-regulated in re-
sponse to xenobiotics or stimuli that indicate harsh condi-
tions. One such condition is hypoxia, which is known to
influence expression via the binding of Hypoxia Inducible
Factor (HIF) complexes to ABC transporter promoters
[59]. Oxidative stress is also known to stimulate ABC trans-
porter expression, for example activation of the ABCG2
promoter can be mediated by the transcription factor
NRF2 under such conditions [60]. It is possible that this,
or alternate transcription systems that detect oxidative
stress or cellular damage, may be responsible for up-
regulating ABC transporter family members after irradi-
ation in medulloblastoma.
The fact that observed gene expression changes upon
irradiation in R001 and R026 cells were more similar to
each other than to other investigated cells led us to in-
vestigate the subtype classification for these patients.
Both were found to represent “Group 3” tumors by 22
gene signature nanoString nCounter analysis ([61] and
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been analyzed by other researchers [62], and found to be
of the SHH subtype. This may in part explain the vari-
ability observed between the responses, particularly since
elevation of ABCG2 in response to radiation was ob-
served for UW228 and Daoy but not for R001 or R026.
The transcription of certain ABC transporter genes, in-
cluding ABCG2, is known to be directly influenced by
activation of the Hedgehog signaling pathway [63-65].
While ABC transporter related responses to drugs have
been investigated by numerous groups, a functional role
for ABC transporters in radiation protection remained
largely unexplored prior to our studies. However, a hy-
pothetical radio-protective role has previously been
proposed [66], and a precedent for the transport of mol-
ecules as a mechanism of radiation protection does
exist, with the non-ABC transporter RLIP76 known to
play a key role in glutathione-mediated radiation pro-
tection in non-cancerous cells [67]. ABC transporters
may potentially protect cells from radiation via direct
transport of toxic radiation by-products from cells, by
moderating glutathione balance, or by actively removing
glutathione-bound conjugates. Alternatively, the effect
may be more indirect, such as ABC transporters shuttling
post-irradiation “messenger molecules” between compart-
ments or cells. Such effects could in turn trigger DNA re-
pair or modulate the apoptotic response in order to
enhance cell survival. There is evidence from leukemia
cells suggesting that verapamil-reversible drug resistance
can be driven by glutathione based systems, rather than
drug efflux [66]. Additionally, over-expression of ABCB1
in hematopoietic cells appears to reduce apoptosis [68].
ABC transporters may contribute to radiation resistance
via similar means. Elucidation of the exact mechanism
awaits further study.
In light of our findings supporting a functional role for
ABC transporters in radiation protection, two previous
studies are of note. In 2009 a stem-like sub-population of
bladder cancer cells with high ABC transporter activity
was shown to be sensitized to radiation in the presence of
verapamil [69]. This study did not attempt to determine if
this was mediated by cation channel effects or ABC trans-
porter blockade. Our findings show pediatric medulloblas-
toma behaves similarly, and that the mechanism is likely
to be independent of cation effects. Further evidence
supporting our finding of ABC transporters as mediators
of radiation resistance comes from a study of breast
cancer patients. A single nucleotide polymorphism screen
has previously shown that patients harboring an amino
acid change in ABCA1 tend to suffer radiation induced
dermatitis during therapy [70], implying ABCA1 is a
contributor to cellular radio-protection, at least in some
cell types. While the exact combination of members in this
large family that play a role in the radiation tolerancephenotype is yet to be determined, our finding that certain
multi-ABC transporter inhibitors can sensitize cells to
radiation whilst single transporter specific agents lack an
effect, indicates that a number of ABC transporter
proteins are involved, probably with redundant functions.
We utilized a large publicly available dataset [38], to
complement our initial qRT-PCR study and provide the
first family-wide survey of ABC transporter expression in
medulloblastoma. The observed variation in expression
patterns contributes to our finding that ABC transporter
inhibitors give differing effects on radiation tolerance de-
pending on the patient that cell cultures are derived from.
Our analysis of publicly available microarray data
showed that the expression level for several ABC trans-
porter family genes is strongly associated with particular
medulloblastoma subtypes. This was particularly evident
with ABCA8, ABCC8 ABCD2 and ABCB4. Potential cor-
relations between ABC transporter expression and re-
lapse/clinical progression will be explored as our cohort
matures. This information was not available for the
dataset used for the discovery of subtype related associa-
tions, however evidence from multiple groups has shown
robust correlation between subtype and clinical outcome
(in particular a relatively favorable outcome for WNT
driven tumors and a poorer than average outcome for
“Group 3” medulloblastoma) [39,71,72].
The fact that certain ABC transporters show distinct
patterns of expression for particular subtypes, and that the
proteins are membrane localized, makes them attractive
candidates as novel diagnostic markers (particularly for
discriminating between SHH and non-SHH pathway
driven tumors). In will be interesting in future studies to
see if this association also extends to other tumor types.
Whether the suite of ABC transporters that play a role
in radiation protection overlap with the family members
that show strong subtype dependent expression patterns
is also of particular interest for future study. Further
study of ABC transporters stands to provide key insights
into the biology of how certain cancer cells evade
radiation-induced death.
Conclusions
Our work provides proof of principle for a novel method
of enrichment for radiation tolerant medulloblastoma
cells isolated early after gamma ray exposure. We further
demonstrate that these tolerant cells retain tumor initiat-
ing properties. Success with an initial candidate set has
provided insight into the expression of genes related to
stem-like biology in cells that survive radiation exposure.
The observed elevation of ABC transporter expression
in these cells has implications for the order in which
treatments are delivered to patients, as increased efflux
pump activity may reduce the efficacy of chemothera-
peutic drugs that are delivered after radiotherapy.
Table 1 Human medulloblastoma patients for which
tumor tissue was used for gene expression and/or culture
experiments
Patient
ID
Pathology at diagnosis
R001 Medulloblastoma, classic
R002 Medulloblastoma, classic
R014 Medulloblastoma, classic
R017 Medulloblastoma, classic
R026 Medulloblastoma, poorly differentiated classic
R029 Reported by independent pathologists as 1)
Medulloblastoma and 2) unusual AT/RT-like tumor (without
INI1 loss)
R032 Medulloblastoma, classic, with metastatic nodule nearby
R034 Medulloblastoma, classic
R060 Medulloblastoma, with extensive nodularity
MB001 Medulloblastoma, recurrent
MB005 Medulloblastoma, recurrent
MB008 Medulloblastoma, desmoplastic
MB009 Medulloblastoma, classic
MB010 Medulloblastoma, classic
MB012 Medulloblastoma, classic
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that ABC transporter proteins contribute to cellular radi-
ation protection mechanisms. Our in vitro studies suggest
that multiple ABC transporter proteins likely act in con-
cert to contribute to radiation tolerance in human medul-
loblastoma cells. The fact that broad spectrum inhibitors
significantly sensitize cells, whilst those targeting individ-
ual ABC transporters do not, suggests an overlap in the
roles of the various family members involved in this newly
detected mechanism for radiation protection.
Although clinical trials of ABC transport inhibiting
compounds aimed at circumventing chemotherapy re-
sistance initially hit obstacles, promising “new gener-
ation” anti-ABC transporter drugs are now at various
stages of pre-clinical and clinical assessment [9,73,74].
Our work suggests such compounds, if they inhibit mul-
tiple transporters, could potentially provide additional
benefits for patients if they are delivered during radi-
ation as well as chemotherapy treatment.
Most importantly we also show, through analysis of pub-
lically available gene expression data sets, that certain ABC
transporters contribute to gene expression signatures for
particular molecular subtypes of medulloblastoma, a find-
ing which could be exploited in future prognostic tests.MB015 Medulloblastoma, classic
MB017 Medulloblastoma, classic
MB018 Medulloblastoma, desmoplastic
MB021 Medulloblastoma, classic
MB022 Medulloblastoma, classic
MB024 Medulloblastoma, classic
MB026 Medulloblastoma, classic
MB027 Medulloblastoma, classic
MB028 Medulloblastoma, classic
MB029 Medulloblastoma, classic
MB031 Medulloblastoma, recurrent
MB033 Medulloblastoma, classic
MB034 Medulloblastoma, classic
MB035 Medulloblastoma, classic
MB037 Medulloblastoma, classic
MB038 Medulloblastoma, classic
MB039 Medulloblastoma, classic
MB040 Medulloblastoma, desmoplastic
MB041 Medulloblastoma, desmoplasticMaterials and methods
Medulloblastoma patient tissue, lines and culture
conditions
Both Daoy (desmoplastic variant, from American Type
Culture Collection; HTB-186) and UW228 cells were
cultured in MEM alpha with 9.1% fetal bovine serum
(FBS) [75,76]. Fresh medulloblastoma tissue was obtai-
ned from patients at the time of surgery. Portions were
snap frozen for later RNA extraction and the remainder
was finely chopped with a scalpel and cultured in
DMEM/F12 with 9.1% FBS. After one week, growing ex-
plants were trypsinized and seeded for continuing adher-
ent cell culture. Monolayer cultures from patients R001
and R026 (designated R001M and R026M) were used in
experiments prior to passage 15. Tumorspheres were
cultured using neurosphere conditions [77]. All culture
reagents were obtained from Invitrogen. Patient material
was ethically consented and used in accordance with
approvals from The University of Queensland Human
Research Ethics Committee (HREC) and the Queensland
Children's Health Services (RCH) HREC (approval
#2006000106 and #2005/077 respectively). Further ethic-
ally consented medulloblastoma and normal pediatric
cerebellum samples (from autopsies after fatal trauma),
were obtained from the Fred Hutchinson Cancer Research
Center, Seattle, USA. Clinical details for investigated
patients are given in Table 1. All human subject work
conformed to the Helsinki Declaration (2008 revision).Radiation exposure
Cells were seeded and allowed to adhere for two to five
hours prior to radiation delivery via a Gammacell 40 irra-
diator (Nordion). For survivor cell enrichment, cells were
exposed to a single 10 Gy dose (except for R026M for
which 60 Gy was used) and FACS performed three days
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ted weekly radiation exposure were rested for one week
after the final dose, before gene expression analysis was
undertaken. This delay was to ensure that any potential
“stress effects” of the radiation treatment itself would not
confound analysis of the surviving populations.
Immunofluorescence and flow cytometry
PS externalization was detected using Annexin V conju-
gated to Alexa 488 or Pacific Blue (#A13201 or #A35122,
Invitrogen). Dead cells were detected with PI or 7-ADD
(#P21493 or #A1310, Invitrogen). Immunofluorescence
was performed using standard methods after fixation with
4% paraformaldehyde. A FACS ARIA Cell Sorter was used
for cell isolation and a FACS Canto II for general flow cy-
tometry (both BD Biosciences). ABCG2 was detected with
an Alexa Fluor 700 labeled antibody (#332016; BioLegend)
and ABCA1 with a DyLight 488 conjugate (#NB400-
105G; Novus Biologicals).
Treatment with channel blocking compounds
Verapamil (R and S mixture), R-verapamil and S-
verapamil were from Sigma-Aldrich (#V4629, #V106
and #V105 respectively). Other inhibitors were also
obtained from Sigma-Aldrich, except for the ABCG2 spe-
cific blockers fumitremorgin C (FTC) and Ko143, which
were from Enzo Life Sciences (#ALX-350-127-C250 and
#BML-EI396-0025) [78]. Stocks were prepared in ethanol
or dimethyl sulfoxide (DMSO) as appropriate, and the car-
rier used as a control. Compounds were used at 50 μM
unless otherwise stated, with the exception of FTC, Ko143
and reserpine, which were routinely used at 10 μM. Drugs
were added 1 to 2 hours before radiation treatment for in-
hibitor screening. Media was changed post-irradiation and
fresh drug added, to circumvent potential damage to com-
pounds from radiation itself, and fresh media/drug was
again added after 24 hours.
Assessment of cell viability and colony forming ability
Total cellular viability assays were performed in 96 well
plates using the resazurin based “CellTiter-Blue” assay
(#G8081, Promega). A minimum of six replicate assays
were performed per treatment and cells were incubated
for five to nine days post-treatment, until control wells
were 90% confluent. Fluorescence was measured using a
Fluorocount reader (Perkin Elmer).
Colony formation was assessed using the Clonogenic
Colony Forming Assay (CCFA). Cells were treated after
seeding at low density then incubated (six days for UW228,
seven days for Daoy and 28 days for R001). A minimum of
five 25 cm2 flasks were used per treatment, such that at
least 2500 cells were assessed. Colonies were counted and
sized from high resolution whole flask digital photographs
with automated image analysis software (Analysis LSResearch, Olympus). Clusters were not counted as colonies
unless cells had achieved five to six population doublings
(minimum mean diameter of 0.4 mm) [79].
RNA and gene expression analysis
RNA was prepared with RNeasy columns (#74104,
Qiagen). Synthesis of cDNA was carried out with Super-
script III (#18080-085, Invitrogen) and qRT-PCR was
performed with an ABI 7900HT system using TaqMan
gene expression assay primer-probe sets (Applied
Biosystems). Relative expression was determined using
ΔCts, from triplicate or quadruplicate reactions, using
multiplexed GAPDH as the endogenous reference.
Subgroup affiliations for tumors from patients R001
and R026 were determined using nanoString-based tar-
geted gene expression profiling as previously described
[61]. Normalization of nanoString data and subgroup
prediction were performed using the R statistical envir-
onment (v 2.15), as previously described [61].
The publicly available medulloblastoma gene expres-
sion array data used for initial analysis was obtained
from the National Center for Biotechnology Informa-
tion (NCBI) Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/geo/; identifier GSE10327 [38])
and analyzed using the NCBI GEO2R package. Signifi-
cance testing was performed conservatively using the
Benjamini and Hochberg multiple-testing correction, to
minimize the false discovery rate [80].
Validation data from three further cohorts (“Boston”
[40], “Toronto” [41] and “Heidelberg” [42,43]), were ana-
lyzed using R2 (http://hgserver1.amc.nl/cgi-bin/r2/main.
cgi). The KEGG geneset annotated as “ABC trans-
porters” was visualized using heat maps according to
subgroup affiliation and in normal tissue if applicable.
One-way ANOVA and post-hoc comparisons were used
to determine gene expression differences across sub-
groups and between subgroups, respectively. P-values
below 0.05 were considered significant.
Murine xenograft models for in vivo human tumor growth
Orthotopic cerebellar xenografts were performed using
a stereotaxic platform and micro-drill to make a burr
hole 1 mm lateral to the sagittal suture and 1 mm pos-
terior to the lambdoidal suture. 100,000 cells were then
injected 3 mm below the skull surface using a Hamilton
syringe (delivered over three minutes and needle
withdrawn slowly after a further minute). For in vivo
tumorigenicity testing after in vitro verapamil exposure,
50 μM of drug was added to cells in culture and media
changed and fresh drug added after 24 hours. The cells
were then incubated for a further four days before
trypsinization and delivery of 200,000 live cells per
injection. Cells were delivered subcutaneously in the
lateral mid-flank, in a 200 μl volume with 50% matrigel
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presence of palpable tumors twice per week thereafter.
All experiments used female severe combined immu-
nodeficiency mice. Animal studies were performed in
accordance with approvals obtained from the Health
Sciences Animal Ethics Committee of The University of
Queensland (approval #RCH/118/09).
Statistical analyses
Significance testing of large scale gene expression data is
outlined above. For other experiments, statistical analysis
was performed using GraphPad Prism5 software. For
qRT-PCR data (presented as the level of expression for
the gene of interest relative to GAPDH), significance
was assessed using the ratio t-test (two-tailed paired t-test
on log transformed data). Error bars on CCFA and viabil-
ity assay graphs represent the standard deviation (SD) for
the numerator (treated) and denominator (control) com-
ponents of each survival calculation, combined (as per-
centages of the associated means) using the “square root
of the sum of squares” technique. Tumor formation in
mice over time was assessed using the log-rank (Mantel-
Cox) test. For all other experiments, p-values were derived
using two-tailed t-tests.
Additional files
Additional file 1: Expression profiles for ABC transporters of
particular interest, by molecular medulloblastoma subtype.
Expression patterns from GEO2R analysis of dataset NCBI GEO GSE10327
(62 human medulloblastoma cases, organized by subtype), for ABCA1
and four key modulators of drug resistance in human cells (ABCG2,
ABCB1, ABCC1 and ABCC2).
Additional file 2: Differential expression analysis summary for all
ABC transporter family genes present in dataset NCBI GEO
GSE10327, by molecular subtype. Statistical significance data matrix for
all subtype comparisons with all represented ABC gene family members
(in 62 medulloblastoma cases), by GEO2R analysis. Relationships with
p-values < 0.001 are highlighted.
Additional file 3: Expression profiles for four ABC transporters that
show highly significant medulloblastoma subtype associations.
Expression patterns from GEO2R analysis of dataset NCBI GEO GSE10327
(62 human medulloblastoma cases), for ABC transporters found to have
combinatorial subtype discrimination p-values < 0.000001 (ABCA8, ABCC8,
ABCD2 and ABCB4).
Additional file 4: Medulloblastoma Gene Expression Heat Maps for
ABC Transporter Family Members. Expression data for available ABC
Transporter genes in the Boston and Toronto sets, shown as heat
maps (over-expression = red, under-expression = green). Patients are
ordered by molecular subtype and clustered by ABC expression pattern.
Additional file 5: ABCA1 is highly expressed in WNT driven
medulloblastoma, relative to other subgroups and normal
cerebellum. ABCA1 expression data from the three independent validation
cohorts (n = 366 patients total), shown as box and whisker plots (quartiles
and median indicated by box outline and centreline respectively). Asterisks
indicate significance of difference in expression between the WNT tumors
and the remaining subgroups (“***” = p-value <0.001). In addition,
comparison between the WNT subgroup and normal cerebellum
(available for the Boston cohort) showed a significant difference, with
a p-value < 0.001.Abbreviations
ABC: ATP-binding cassette; CCFA: Clonogenic colony forming assay;
CNS: Central nervous system; CSC: Cancer stem-like cell;
DMEM/F12: Dulbecco's modified eagle medium/nutrient mixture F-12;
DMSO: Dimethyl sulfoxide; FACS: Fluorescence-activated cell sorting;
FTC: Fumitremorgin C; FBS: Fetal bovine serum; PI: Propidium iodide;
PS: Phosphatidylserine; qRT-PCR: Quantitative real-time PCR; SD: Standard
deviation; SHH: Sonic hedgehog.
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